H. J. Pasanen-m, . Purkunen-r, . Saarikoski-s, . Pelkonen-o, and R. A. Maenpaa-j, Expression of xenobiotic-mctabolizing cytochrome P450 forrns in human adult and fetal liver

T. W. Veronese-m, 8. D. Gonzalez-f, and . Minersj, Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2El using cDNA expression and microsomal kinetic techniques

S. D. Griffiths-a, . H. Miller-j, and . Lewontin-re, Introduction à l'analyse génétique

1. , P. H. , K. N. , P. M. , and P. B. Park-s, Expression of cytochrome P4502E1 in human liver : assessment by mRNA, genotype and phenotype, Pharmacogenetics J!, pp.41-42, 1998.

C. V. Berthou-f, B. S. Beaune-p, and . De, Human cytochrome P450 2EI (CVP 2E1) : from genotype to phenotype, Pharmacogenetics, vol.3, pp.203-205, 1996.

L. M. Casson-a, . N. Wolf-c, . J. Hardie-l, . B. Flinterman-m, . Montesano-r et al., Characterization of cytochrome P450 expression in human oesophageal mucosa, Carcinogenesis, vol.20, issue.2, pp.243-248, 1999.

H. J. Mantyla-m, . Kangas-l, P. Wrnrx, H. J. Paaki-p, and E. S. Pelkonen-o, Expression of cytochrome P450 genes encod ing enzymes active in the metabo lism of tamoxifen in human ute rine endometrium

2. Delon, Induction enzymat ique hépatique du cytochro me P450. Applicati on à l'étude d es intéractions : rifarnpicine/ prednisone et ph énobarbital

G. 1. Ove, . J. St, . A. Brown, Y. A. Dal, N. M. Basse et al., The RsaI polymorphism of CYP2E I and susceptibility to alco holic liver disease in Caucasians : effect on age of presentation

C. M. , V. L. Mo-ltke-l, and G. I. Srade-r-r, Biotransformation of chlorzoxazone by hepatic microsomes from hum ans and ten other mammalian species

G. A. , L. D. , M. J. Seltz, and H. K. , Chlomethiazole inhibition of cytochrome P450 2E 1 as assessed by chlorzoxazone hydroxylation in humans

O. , S. D. Kim-n.-n, and W. G. , Modulation of CYP2E1 activity by isonia zid in rapid and slow N-acetylors

P. M. , K. N. , Q. L. , A. Lott-rl, . J. Green-v et al., Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease ln Caucasians, Pharmacogenetics, vol.1, issue.6, pp.995-351

L. Pfiz and E. , Précis de poche de pharmacocinétique Par is : Pfizer, 1993.

V. Ks, A. De, and A. T. Seat, Studies on interindividual variations of CVP2E 1 using chlorzoxazon e as an in vivo prob e, Pharmacogenetics, vol.2, pp.53-57, 1995.

K. M. Vang-o and . Cla, Effects of dietary broccoli on human in vivo drug metabolizing enzymes : evaluation of caffeine, oestrone and chlorzoxazo ne metabolism, Carcinogenesis, vol.17, pp.793-799, 1996.

L. 1. Horsmans-y, D. J. , P. S. , and G. A. , Dietary restriction of energy and sugar results in a reduction in human cytochrome

I. S. Nomura-f, . Harada-s, T. S. Tsuts-um-i-m, and . Naka-i-t, Mutations in the exons and exon-intron junction regions of human

F. , S. , G. J. De-waziers-1, D. T. Stelmel, C. R. Day-c et al., K Detection and characterization of novel poly morphis ms in the CVP2E 1 gene, Pharmacogenetics, vol.1, pp.543-552, 1998.

D. De, R. En-pharmacie-présenté-par, M. M. Elouardi-melle, and . Galtea-u, Polymorphisme génétique du CYP2E 1 et susceptibilité à l'alcool Président, 2000.